Loading
Latest filing published 17 May 2023 for iSpecimen Inc..
Based on 3 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Steven R. Gullans PhD discloses dealings in 3 companies, chiefly MetaVia Inc., Tetraphase Pharmaceuticals Inc and iSpecimen Inc. Over a trading history stretching from 25 March 2013 to 1 January 2023, the count stands at 9 filings.
The open-market record is one-sided, with 5 purchases worth €8.2M and not one sale. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Other entries cover 2 share grants.
A typical purchase (the median) is worth €473k. Of 3 purchases, 3 formed part of a group of insiders buying within 30 days of each other. Purchases made close together by different insiders form what is called a cluster. For 3 purchases whose 90-day window has closed, the share price was higher on day 90 than the day after publication in 33% of cases, with a median move of -7.7%. Past outcomes like these are no guarantee of what comes next.
Most recently, on 17 May 2023, the filings show a share grant in iSpecimen Inc. The clock since the last published purchase (12 February 2018) now reads 3,177 days. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. US insiders must file a Form 4 within two business days of a trade. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
8 of 8 declarations